Massachusetts Financial Services Co. MA Sells 10,328 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

Massachusetts Financial Services Co. MA lessened its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGOFree Report) by 3.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 269,514 shares of the company’s stock after selling 10,328 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Organogenesis were worth $857,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in ORGO. Ameritas Investment Partners Inc. increased its holdings in Organogenesis by 80.1% during the first quarter. Ameritas Investment Partners Inc. now owns 5,386 shares of the company’s stock worth $41,000 after buying an additional 2,396 shares during the last quarter. Point72 Hong Kong Ltd increased its holdings in shares of Organogenesis by 245.7% in the second quarter. Point72 Hong Kong Ltd now owns 6,015 shares of the company’s stock valued at $29,000 after purchasing an additional 4,275 shares during the last quarter. Lazard Asset Management LLC increased its holdings in shares of Organogenesis by 3,808.2% in the first quarter. Lazard Asset Management LLC now owns 9,106 shares of the company’s stock valued at $69,000 after purchasing an additional 8,873 shares during the last quarter. Principal Financial Group Inc. acquired a new position in shares of Organogenesis in the third quarter valued at $32,000. Finally, Great Lakes Advisors LLC acquired a new position in shares of Organogenesis in the second quarter valued at $35,000. Institutional investors own 39.48% of the company’s stock.

Insider Transactions at Organogenesis

In other news, major shareholder Albert Erani sold 197,921 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $4.37, for a total value of $864,914.77. Following the completion of the transaction, the insider now owns 59,025,106 shares of the company’s stock, valued at $257,939,713.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 34.00% of the company’s stock.

Organogenesis Trading Up 5.2 %

ORGO opened at $3.84 on Tuesday. Organogenesis Holdings Inc. has a twelve month low of $1.79 and a twelve month high of $4.70. The company has a 50-day simple moving average of $3.71 and a 200 day simple moving average of $3.05. The company has a quick ratio of 2.43, a current ratio of 2.77 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $507.03 million, a price-to-earnings ratio of 38.40 and a beta of 1.59.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley boosted their target price on shares of Organogenesis from $3.00 to $3.50 and gave the company an “equal weight” rating in a research report on Tuesday, November 14th. BTIG Research boosted their target price on shares of Organogenesis from $4.00 to $6.00 and gave the company a “buy” rating in a research report on Wednesday, December 27th. Finally, Cantor Fitzgerald assumed coverage on shares of Organogenesis in a research report on Wednesday, February 7th. They issued an “overweight” rating and a $5.00 target price for the company.

View Our Latest Report on Organogenesis

Organogenesis Profile

(Free Report)

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly, a antimicrobial barrier that enables conformability and fluid drainage.

Featured Stories

Want to see what other hedge funds are holding ORGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organogenesis Holdings Inc. (NASDAQ:ORGOFree Report).

Institutional Ownership by Quarter for Organogenesis (NASDAQ:ORGO)

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.